ReviewJournal of human immunity2026
How I Treat: Infections and inborn errors of immunity-Prevention, diagnosis, and treatment.
Review in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: Single-center cohort analysis.The Journal of allergy and clinical immunology · 2026Observational
- Cutaneous Manifestations of Inborn Errors of Immunity: Clinical Clues to Immune Disorders.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections are a significant cause of morbidity and mortality in inborn errors of immunity (IEI). Prevention of infections relies on knowledge of the specific pathogen susceptibility of the IEI to then consider antimicrobial prophylaxis, immune modulation, and/or environmental measures. In addition, complications of IEI include bronchiectasis, which can lead to more infections due to disruption of mucociliary clearance; suppression of chronic infections and airway clearance measures are important parts of bronchiectasis management. We discuss some infections that are challenging to diagnose for patients with distinct IEI and how partnership with the microbiology laboratory can lead to more prompt diagnosis and specific management. Finally, the increasing ability to identify the molecular basis of IEI facilitates precise immunomodulation, which can attenuate the infection burden of these diseases yet can also add unique infection risks depending on the specific therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.